Healthcare · Pharmaceuticals: Major

Pfizer Inc.

NYSEPFE ISINUS7170811035 SEC CIK0000078003 Listed on NYSE · USD

$29.10 -0.35 (-1.19%) Pre-market $29.72 (+0.92%) ≈ ₹2,731 a share

Open chart

Price, last 12 months+20.55% in a year

Key numbers

Market value: $165.87B
P/E (TTM): 41.6
Forward P/E: 10.4
EPS (TTM): $0.70
Dividend yield: 5.91%
Beta: 0.30
Day range: $29.08 – $29.77
52-week range: $23.62 – $31.44
Volume: 6,766,994
10-day avg volume: $43.78M
Revenue (TTM): $63.62B
EBITDA (TTM): $25.92B
Gross margin: 74.9%
Net margin: 6.4%
Return on equity: 4.4%
Debt / equity: 70.4%
Price / sales: 2.61
Shares out: 5.70B

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$14.57B$-3.37B

Dec 23

$14.88B$3.12B

Mar 24

$13.28B$41.00M

Jun 24

$17.70B$4.47B

Sep 24

$17.76B$410.00M

Dec 24

$13.72B$2.97B

Mar 25

$14.65B$2.91B

Jun 25

$16.65B$3.54B

Sep 25

$17.56B$-1.65B

Dec 25

$14.45B$2.69B

Mar 26

$15.03B$-248.00M

Jun 26

$16.58B$3.24B

Sep 26

Revenue · QoQ (vs last quarter)

—+2.1%-11%+33%+0.3%-23%+6.8%+14%+5.4%-18%+4.0%+10%

Revenue · YoY (vs a year ago)

————+22%-7.8%+10%-5.9%-1.2%+5.4%+2.6%-0.4%

Net income · QoQ (vs last quarter)

—+192%-99%+10,790%-91%+624%-1.9%+22%-147%+263%-109%+1,407%

Net income · YoY (vs a year ago)

————+112%-4.8%+6,998%-21%-502%-9.4%-109%-8.4%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$14.57B	$14.88B	$13.28B	$17.70B	$17.76B	$13.72B	$14.65B	$16.65B	$17.56B	$14.45B	$15.03B	$16.58B
Cost of revenue	$7.56B	$3.38B	$3.30B	$5.26B	$5.91B	$2.85B	$3.78B	$4.17B	$5.27B	$3.55B	$4.09B	$4.03B
Gross profit	$7.01B	$11.50B	$9.98B	$12.44B	$11.85B	$10.87B	$10.88B	$12.48B	$12.29B	$10.90B	$10.94B	$12.56B
Gross margin	48.1%	77.3%	75.2%	70.3%	66.7%	79.3%	74.2%	74.9%	70.0%	75.4%	72.8%	75.7%
Selling, general & admin	$4.58B	$3.50B	$3.72B	$3.24B	$4.27B	$3.03B	$3.42B	$3.19B	$4.16B	$2.96B	$3.41B	$3.28B
Interest expense	$688.00M	$790.00M	$778.00M	$783.00M	$740.00M	$654.00M	$654.00M	$652.00M	$711.00M	$668.00M	$667.00M	$662.00M
Pre-tax income	$-4.13B	$3.42B	$-103.00M	$4.72B	$-10.00M	$2.79B	$3.04B	$3.33B	$-1.64B	$3.17B	$-653.00M	$3.39B
Income tax	$-795.00M	$293.00M	$-134.00M	$234.00M	$-421.00M	$-189.00M	$141.00M	$-216.00M	$-2.00M	$461.00M	$-407.00M	$134.00M
Net income	$-3.37B	$3.12B	$41.00M	$4.47B	$410.00M	$2.97B	$2.91B	$3.54B	$-1.65B	$2.69B	$-248.00M	$3.24B
Net margin	-23.1%	20.9%	0.3%	25.2%	2.3%	21.6%	19.9%	21.3%	-9.4%	18.6%	-1.6%	19.6%
EPS (diluted)	—	$0.55	$0.01	$0.78	—	$0.52	$0.51	$0.62	—	$0.47	$-0.04	$0.56

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$40.83B$31.84B$11.15B

FY18

$40.91B$32.85B$16.03B

FY19

$41.65B$33.17B$9.16B

FY20

$81.29B$50.47B$21.98B

FY21

$101.18B$66.83B$31.37B

FY22

$59.55B$34.60B$2.12B

FY23

$63.63B$45.78B$8.03B

FY24

$62.58B$46.51B$7.77B

FY25

Revenue · YoY (vs a year ago)

—+0.2%+1.8%+95%+24%-41%+6.8%-1.6%

Net income · YoY (vs a year ago)

—+44%-43%+140%+43%-93%+279%-3.2%

RevenueGross profitNet incomeLine = trend

$1.87

FY18

$2.82

FY19

$1.63

FY20

$3.85

FY21

$5.47

FY22

$0.37

FY23

$1.41

FY24

$1.36

FY25

EPS (diluted) · YoY (vs a year ago)

—+51%-42%+136%+42%-93%+281%-3.5%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$40.83B	$40.91B	$41.65B	$81.29B	$101.18B	$59.55B	$63.63B	$62.58B
Revenue growth	—	0.2%	1.8%	95.2%	24.5%	-41.1%	6.8%	-1.6%
Cost of revenue	$8.99B	$8.05B	$8.48B	$30.82B	$34.34B	$24.95B	$17.85B	$16.07B
Gross profit	$31.84B	$32.85B	$33.17B	$50.47B	$66.83B	$34.60B	$45.78B	$46.51B
Gross margin	78.0%	80.3%	79.6%	62.1%	66.1%	58.1%	71.9%	74.3%
Selling, general & admin	$12.61B	$12.73B	$11.60B	$12.70B	$13.68B	$14.77B	$14.73B	$13.79B
Depreciation & amortisation	$6.38B	$5.76B	$4.68B	$5.19B	$5.06B	$6.29B	$7.01B	$6.59B
Interest expense	$1.32B	$1.57B	$1.45B	$1.29B	$1.24B	$2.21B	$3.09B	$2.67B
Pre-tax income	$3.59B	$11.32B	$7.04B	$24.31B	$34.73B	$1.06B	$8.02B	$7.52B
Income tax	$-266.00M	$583.00M	$370.00M	$1.85B	$3.33B	$-1.12B	$-28.00M	$-266.00M
Tax rate	-7.4%	5.1%	5.3%	7.6%	9.6%	-105.4%	-0.3%	-3.5%
Net income	$11.15B	$16.03B	$9.16B	$21.98B	$31.37B	$2.12B	$8.03B	$7.77B
Net margin	27.3%	39.2%	22.0%	27.0%	31.0%	3.6%	12.6%	12.4%
EPS (diluted)	$1.87	$2.82	$1.63	$3.85	$5.47	$0.37	$1.41	$1.36

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$63.41B$37.69B$18.83B

FY18

$63.14B$37.42B$9.65B

FY19

$63.24B$39.14B$12.22B

FY20

$77.20B$37.83B$23.96B

FY21

$95.66B$35.44B$19.16B

FY22

$89.01B$63.79B$7.25B

FY23

$88.20B$61.15B$11.92B

FY24

$86.48B$64.64B$10.33B

FY25

Shareholders' equity · YoY (vs a year ago)

—-0.4%+0.2%+22%+24%-6.9%-0.9%-2.0%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$1.14B	$1.12B	$1.79B	$1.94B	$416.00M	$2.85B	$1.04B	$1.14B
Short-term investments	$17.69B	$8.53B	$10.44B	$22.01B	$18.74B	$4.40B	$10.88B	$9.18B
Current assets	$49.93B	$32.80B	$35.07B	$59.69B	$51.26B	$43.33B	$50.36B	$42.90B
Total assets	$159.42B	$167.59B	$154.23B	$181.48B	$197.21B	$226.50B	$213.40B	$208.16B
Current liabilities	$31.86B	$37.30B	$25.92B	$42.67B	$42.14B	$47.79B	$43.00B	$36.98B
Long-term debt	$32.91B	$35.96B	$37.13B	$36.20B	$32.88B	$61.54B	$57.41B	$61.64B
Short-term debt	$4.78B	$1.46B	$2.00B	$1.64B	$2.56B	$2.25B	$3.75B	$3.00B
Total debt	$37.69B	$37.42B	$39.14B	$37.83B	$35.44B	$63.79B	$61.15B	$64.64B
Total liabilities	$95.66B	$104.15B	$90.76B	$104.01B	$101.29B	$137.21B	$124.90B	$121.39B
Shareholders' equity	$63.41B	$63.14B	$63.24B	$77.20B	$95.66B	$89.01B	$88.20B	$86.48B
Current ratio	1.57	0.88	1.35	1.40	1.22	0.91	1.17	1.16
Debt / equity	0.59	0.59	0.62	0.49	0.37	0.72	0.69	0.75
Return on equity	17.6%	25.4%	14.5%	28.5%	32.8%	2.4%	9.1%	9.0%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$15.83B$13.84B$12.20B

FY18

$12.59B$10.54B$8.87B

FY19

$14.40B$12.18B$0

FY20

$32.58B$29.87B$0

FY21

$29.27B$26.03B$2.00B

FY22

$8.70B$4.79B$0

FY23

$12.74B$9.84B$0

FY24

$11.70B$9.08B

FY25

Operating cash flow · YoY (vs a year ago)

—-20%+14%+126%-10%-70%+46%-8.2%

Free cash flow · YoY (vs a year ago)

—-24%+16%+145%-13%-82%+105%-7.7%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$15.83B	$12.59B	$14.40B	$32.58B	$29.27B	$8.70B	$12.74B	$11.70B
Capital spending	$-1.98B	$-2.05B	$-2.23B	$-2.71B	$-3.24B	$-3.91B	$-2.91B	$-2.63B
Free cash flow	$13.84B	$10.54B	$12.18B	$29.87B	$26.03B	$4.79B	$9.84B	$9.08B
FCF margin	33.9%	25.8%	29.2%	36.7%	25.7%	8.0%	15.5%	14.5%
Stock-based pay	$923.00M	$687.00M	$755.00M	$1.18B	$872.00M	$525.00M	$877.00M	$799.00M
Cash from investing	$4.53B	$-3.95B	$-4.27B	$-22.55B	$-15.78B	$-32.28B	$2.65B	$-1.35B
Cash from financing	$-20.44B	$-8.49B	$-9.65B	$-9.82B	$-14.83B	$26.07B	$-17.14B	$-10.30B
Share buybacks	$-12.20B	$-8.87B	$0	$0	$-2.00B	$0	$0	—

About

About Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Pfizer Inc.
Ticker: PFE
Exchange: NYSE
ISIN: US7170811035
SEC CIK: 0000078003
Sector: Healthcare
Industry: Pharmaceuticals: Major
SEC industry (SIC): Pharmaceutical Preparations (2834)
Incorporated in: Delaware
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 26 Feb 2026
CEO: Albert Bourla
Chair: Albert Bourla
Headquarters: New York City
Address: 66 Hudson Boulevard East, New York, Ny 10001-2192
Founded: 1849
Employees: 75,000
Trades in: US dollars (USD)
Website: pfizer.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Pfizer Inc.

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers